Literature DB >> 17215261

Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor?

D P M Symmons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17215261     DOI： 10.1093/rheumatology/kel418

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  9 in total

1.  Early diagnosis of rheumatoid arthritis: an introduction to the newly designed Iran Criteria for Rheumatoid Arthritis.

Authors:  Iraj Salehi; Shabnam Khazaeli; Mohammad Khak
Journal:  Rheumatol Int       Date:  2012-01-04       Impact factor: 2.631

2.  Predictive value of anti-citrullinated peptide antibodies: a real life experience.

Authors:  Abdulla Watad; Nancy Agmon-Levin; Boris Gilburd; Merav Lidar; Howard Amital; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population?

Authors:  Monchand Vanichapuntu; Puchaniyada Phuekfon; Parawee Suwannalai; Oravan Verasertniyom; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2009-07-12       Impact factor: 2.631

4.  Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis.

Authors:  Jinxia Zhao; Xiangyuan Liu; Zhimin Wang; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2009-10-15       Impact factor: 2.980

5.  Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.

Authors:  K P Liao; K L Batra; L Chibnik; P H Schur; K H Costenbader
Journal:  Ann Rheum Dis       Date:  2008-01-30       Impact factor: 19.103

6.  The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.

Authors:  Maria D Mjaavatten; Désirée van der Heijde; Till Uhlig; Anne J Haugen; Halvor Nygaard; Göran Sidenvall; Knut Helgetveit; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2010-05-05       Impact factor: 5.156

7.  Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies.

Authors:  Tracey M Farragher; Mark Lunt; Darren Plant; Diane K Bunn; Anne Barton; Deborah P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

8.  Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.

Authors:  Chun Li; Yan Zhang; Hui Song; Jie Gao; Dong-Bao Zhao; Qi Zhu; Dong-Yi He; Li Wang; Xiang-Pei Li; Xu-Dong Liu; Wei-Guo Xiao; Xin-Yu Wu; Hua-Xiang Wu; Wei Tu; Shao-Xian Hu; Xin Wang; Zhi-Jun Li; Zhi-Min Lu; Zhan-Yun Da; Bo Liang; Xiao-Min Liu; Jin-Wei Zhao; Ling Li; Feng Han; Wu-Fang Qi; Wei Wei; Xu Ma; Zhen-Bin Li; Gui-Min Zheng; Feng-Xiao Zhang; Yi Li; You-Lian Wang; Guang-Hui Ling; Jin-Wei Chen; Xiao-Qiang Hou; Jing Zhang; Qing-Ping Chen; Chang-Lian Liu; Yan Zhang; Jia-Shun Zeng; Qing-Hua Zou; Yong-Fei Fang; Yin Su; Zhan-Guo Li
Journal:  Chin Med J (Engl)       Date:  2019-12-20       Impact factor: 2.628

9.  Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort.

Authors:  Maria D Mjaavatten; Till Uhlig; Anne J Haugen; Halvor Nygaard; Göran Sidenvall; Knut Helgetveit; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-10-01       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.